Joseph P. Lyssikatos Sells 527 Shares of Enliven Therapeutics, Inc. (NASDAQ:ELVN) Stock

Enliven Therapeutics, Inc. (NASDAQ:ELVN) insider Joseph P. Lyssikatos sold 527 shares of Enliven Therapeutics stock in a transaction on Tuesday, October 1st. The stock was sold at an average price of $27.54, for a total value of $14,513.58. Following the completion of the transaction, the insider now owns 1,077,409 shares in the company, valued at $29,671,843.86. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink.

Enliven Therapeutics Trading Up 0.8 %

Shares of NASDAQ ELVN traded up $0.21 during midday trading on Thursday, reaching $25.51. The company’s stock had a trading volume of 308,043 shares, compared to its average volume of 262,300. Enliven Therapeutics, Inc. has a fifty-two week low of $9.80 and a fifty-two week high of $27.67. The stock has a 50 day simple moving average of $23.19 and a 200-day simple moving average of $21.84. The stock has a market capitalization of $1.20 billion, a price-to-earnings ratio of -12.82 and a beta of 1.09.

Enliven Therapeutics (NASDAQ:ELVN) last issued its earnings results on Tuesday, August 13th. The company reported ($0.41) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.58) by $0.17. As a group, equities analysts anticipate that Enliven Therapeutics, Inc. will post -1.98 EPS for the current year.

Institutional Inflows and Outflows

A number of hedge funds have recently added to or reduced their stakes in ELVN. Quest Partners LLC lifted its stake in shares of Enliven Therapeutics by 87.3% in the second quarter. Quest Partners LLC now owns 1,592 shares of the company’s stock worth $37,000 after acquiring an additional 742 shares during the period. China Universal Asset Management Co. Ltd. increased its holdings in Enliven Therapeutics by 67.0% during the 1st quarter. China Universal Asset Management Co. Ltd. now owns 7,952 shares of the company’s stock worth $140,000 after purchasing an additional 3,189 shares in the last quarter. American Century Companies Inc. lifted its stake in Enliven Therapeutics by 44.7% during the 2nd quarter. American Century Companies Inc. now owns 27,651 shares of the company’s stock valued at $646,000 after acquiring an additional 8,540 shares in the last quarter. EntryPoint Capital LLC bought a new position in shares of Enliven Therapeutics during the first quarter valued at about $167,000. Finally, SG Americas Securities LLC bought a new position in shares of Enliven Therapeutics in the third quarter valued at approximately $256,000. 95.08% of the stock is owned by institutional investors.

Analysts Set New Price Targets

A number of equities analysts recently commented on ELVN shares. Robert W. Baird assumed coverage on Enliven Therapeutics in a report on Tuesday, June 11th. They issued an “outperform” rating and a $32.00 price objective on the stock. HC Wainwright restated a “buy” rating and set a $37.00 price objective on shares of Enliven Therapeutics in a report on Tuesday. Finally, Baird R W raised Enliven Therapeutics to a “strong-buy” rating in a report on Tuesday, June 11th.

About Enliven Therapeutics

Enliven Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company’s lead product candidates comprise ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial in adults with solid tumors with HER2 alterations.